G-CSF is given routinely to some patients on chemotherapy, including patients with neuroblastoma, to help them ward off infection, but the finding that it boosts cancer growth should make ...

All patients had a risk for FN of at least 20%. One group of patients was randomly assigned to the G-CSF pegfilgrastim during all 6 cycles of chemotherapy, which is the standard of care.

The global Granulocyte-Colony Stimulating Factor (G-CSF) is expected to decline from $7.30 billion in 2019 to $6.91 billion in 2020 at a compound annual growth rate (CAGR) of -5.27%.

Lee Schwartzberg, MD, FACP: While colony-stimulating factors like G-CSF [granulocyte colony-stimulating factor] have revolutionized the approach to chemotherapy-induced neutropenia [CIN] and ...

Neutrophils, once considered simple foot soldiers of innate immunity, are now recognized as complex players in cancer.

Correspondence G-CSF Priming in Acute Myelogenous Leukemia Published November 20, 2003 N Engl J Med 2003;349: 2071 - 2072 DOI: 10.1056/NEJM200311203492115 ...

There is little patient benefit to using granulocyte colony-stimulating factor (G-CSF) to help white blood cell growth and reduce the risk of infection in women with breast cancer, according to a ...

G-CSF has a suspected immunosuppressive effect on peripheral blood stem cell allografts, including the shifting of cytokine production towards a type-2 helper cell response. 13, 14 In addition, G ...

The persuasive Global G-CSF/PEG-G-CSF Market report suggests that the key market players are making moves like product launches, joint ventures, developments, mergers and acquisitions which has ...

Correspondence Published: 14 April 2005 Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes J M Hernández, C Castilla, N C Gutiérrez, I M Isidro, M ...

The global G-CSF (granulocyte colony stimulating factors) market is expected to grow from $7.37 billion in 2021 to $7.99 billion in 2022 at a compound annual growth rate (CAGR) of 8.5%. The growth ...